Skip to main
CLGN
CLGN logo

CLGN Stock Forecast & Price Target

CLGN Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

CollPlant Biotechnologies Ltd is advancing its market position through strategic partnerships, including an expanded agreement with STEMCELL Technologies to enhance the supply of rhCollagen, which is anticipated to drive growth in North America. The differentiation of Collink.3D in 3D bioprinting demonstrates significant improvements in tissue formation attributes, positioning the company to potentially lead in an expanding market for regenerative breast implants and other aesthetic applications. Initiatives such as the establishment of a U.S.-based logistics center and new distribution agreements in Europe are expected to bolster sales and enhance global reach, contributing positively to the company's financial outlook.

Bears say

CollPlant Biotechnologies Ltd faces a challenging financial landscape characterized by limited revenue growth and dependence on a niche market for its proprietary rhCollagen products. The company's reliance on income from business collaborations and sales in highly competitive sectors, including medical aesthetics and 3D bioprinting, raises concerns over its long-term profitability and market penetration. Additionally, the operational presence in multiple regions, while diversified, has not translated into significant financial stability or robust sales figures, further contributing to a negative outlook on the company's stock performance.

CLGN has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of CollPlant Biotechnologies Ltd - ADR and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About CollPlant Biotechnologies Ltd - ADR (CLGN) Forecast

Analysts have given CLGN a Strong Buy based on their latest research and market trends.

According to 2 analysts, CLGN has a Strong Buy consensus rating as of Dec 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $11.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $11.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

CollPlant Biotechnologies Ltd - ADR (CLGN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.